Jun 05, 2023
PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market
May 22, 2023
PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
May 10, 2023
PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
Apr 26, 2023
PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023
Apr 24, 2023
PolyPid to Participate in Upcoming Investor Conferences
Apr 14, 2023
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
Mar 31, 2023
PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds
Mar 29, 2023
PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants
Mar 28, 2023
PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares
Mar 07, 2023
PolyPid to Present at the Barclays Global Healthcare Conference
Displaying 1 - 10 of 14